Introduction: Lipid-derived nanotechnology, particularly liposomes, has advanced drug delivery by enhancing pharmacokinetics and reducing side effects. Camptothesome, a novel nano-vesicular system, improves camptothecin's solubility, stability, and toxicity profile but has limited tumor distribution (~5%). This study enhances tumor targeting by functionalizing Camptothesome with LinTT1, a CendR peptide that binds tumor-specific receptors like NRP-1. The modified Camptothesome shows improved tumor homing and anticancer efficacy, outperforming free CPT and Onivyde in CRC models.
Learning Objectives:
Upon completion, participant will be able to learn peptide-derived nanovesicles
Upon completion, participant will be able to visualize the improved performance of peptide-vesicles
Upon completion, participant will be able to apply this technique to other platforms
